# Anti-Interleukin-6 (IL6) in Calciphylaxis

> **NCT07708038** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Boston Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Calciphylaxis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT07708038
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-09
- **Primary completion:** 2030-03
- **Final completion:** 2030-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708038, "Anti-Interleukin-6 (IL6) in Calciphylaxis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07708038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*